Novo Holdings

Novo A/S is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, and the holding company of the Novo Group and as such the majority shareholder in the publicly listed companies Novo Nordisk A/S and Novozymes A/S. Novo A/S was established in 1999 prior to the demerger of Novo Nordisk A/S, where Novozymes A/S was established as a stand-alone publicly listed company. Novo's purpose and objectives are to manage the Foundation's financial assets and to ensure the Foundation sufficient dividends to cover its grant obligations for medical and scientific research etc. in Scandinavia. Novo A/S attains these objectives through: compliance with the rules and principles which are set out in the Articles of Association of the Novo Nordisk Foundation regarding exercise of the voting rights of A and B shares in Novo Nordisk A/S and Novozymes A/S, respectively, assurance that all companies in which the company has a material influence actively contribute to the development of the Novo Group and operate their business in accordance with the visions and values of the Novo Group, maintenance of a material influence on Novo Nordisk A/S and Novozymes A/S, and investment and financing business including placing of capital in companies and real property domestically and abroad. Novo’s overall investment strategy is thus to maintain ownership of Novo Nordisk’ and Novozymes’ shares at a level just above 25% and to invest dividends from these companies and other income in the life science area as well as in a broad portfolio of financial assets. Novo A/S has since 1999 established itself as an international venture capital partner in the life science area and has invested in over 50 companies in Denmark, Europe and North America. Through its financial investment activities Novo A/S seeks to spread the company’s total financial risk and at the same time to ensure a high return taking into consideration the chosen risk profile. In 2007 Novo A/S together with the Novo Nordisk Foundation established ‘Novo Seeds’. The new program (split into two sub-programs) is aimed at supporting early stage applied research in the life science area in Scandinavia. At the beginning of 2009 Novo A/S launched a new initiative, investing 'growth equity' into promising later stage/commercial stage life science companies. Novo A/S represents the interests of the Novo Nordisk Foundation through participation on the boards of the companies in the Novo Group. The companies in the Novo Group are members of a 'family of companies', independently managed, but sharing a set of common values as set out in the 'Charter for Companies in the Novo Group'. In the Charter these core values, commitments and management principles that companies in the Novo Group should live up to are described.

Sibel Karina Arnes

Associate

Nis Bjørnholt Bak

Principal

Raymond Camahort Ph.D

Principal at Novo Ventures

Lily Chang

Vice President, Growth Investments

Coutanceau Ph.D., Emmanuelle

Partner Novo Seeds

Kartik Dharmadhikari

Partner, Bioindustrial Investments

Aleks Engel

Partner, Novo Holdings (Novo Seeds) and Director, REPAIR Impact Fund

Thomas Grotkjær

Investor and Principal

Kuang He

Vice President, Seed Investments

Stephen van Helden

Principal, Bioindustrial Investments, Growth Investments

Johan Hueffer

Senior Partner, Principal Investments

Jørgensen, Morten Beck

Managing Partner

Navjeewan Khosla

Partner, Novo Holdings Equity Asia

Max Klement Ph.D

Principal, Venture Investments

Nilesh Kumar Ph.D

Senior Principal

Lele, Abhijeet J.

Senior Partner and Head of US Principal Investments

Jeffrey Low

Principal

Heather Ludvigsen

Senior Manager, Venture Investments

Nanna Lüneborg

Principal

Joseph Markson Ph.D

Principal, Venture Investments

Moldt, Peter

Partner

Naveed Siddiqi

Senior Partner, Venture Investments

Jim Trenkle

Partner, Venture Investments

348 past transactions

Ray Therapeutics

Series A in 2023
Ray Therapeutics is a company that creates novel optogenetic gene therapies for patients with blinding diseases. The company develops technology to study and learn about rare retinal diseases, allowing doctors to cure and treat inherited retinal diseases using optogenetics.

Alentis Therapeutics

Series C in 2023
Alentis Therapeutics, the CLDN1 company, is a clinical-stage biotech investigating novel therapeutics for CLDN1+ cancers. Alentis is the pioneering business in the use of anti-CLDN1 ADCs and antibodies to modify and reverse the progression of certain diseases.

Kate Farms

Series C in 2022
Kate Farms specializes in the production of plant-based shakes and formulas for tube-fed adults and children. It develops a formula using organic, plant-based ingredients without the synthetic ingredients and common allergens found in traditional formulas. Kate Farms serves thousands of patients suffering from severe, chronic diseases to less serious medical issues, and is available through prescription and over-the-counter.

Theraxyte

Seed Round in 2022
TheraXyte BioScience is a biotechnology company focused on extracellular vesicle (EV)-mediated drug delivery and novel EV-based therapeutics. It aims to establish a multifunctional EV-based drug delivery platform that can meet the upcoming challenges of various therapeutic applications, driving EV research from the lab bench to the bedside, and making a positive impact on human health by overcoming unsolved challenges with novel EV-based therapeutics. TheraXyte has developed and continuously upgraded its EV-based drug delivery platform, TAXY, which could enable the mass production of modifiable EVs at the GMP manufacturing level, has the capability of effectively payload packaging, and target organs/cells of interest where payload drug molecules/active biological molecules could be effectively released as therapeutics.

Inspirna

Series D in 2022
Inspirna (formerly Rgenix) is a clinical-stage biopharmaceutical company developing first-in-class/best-in-class drug candidates that target critical cancer drivers. Our discovery platform leverages RNA biology to discover novel RNA dysregulated cancer drivers that can be targeted by small molecules and biologics. Clinical programs are first-in-class oral small molecules in development for patients with RAS mutant CRC (RGX-202; Phase 1b) as well as SCLC and NSCLC (RGX-104; Phase 1b/2)

Biosyntia

Series B in 2022
Biosyntia is a biotech startup within synthetic biology and metabolic engineering. We develop biocatalysts at an unprecedented speed and efficiency by employing our patent pending high-throughput screening technology. By developing tailored processes based on biocatalysis, Biosyntia enables production of complex chemical compounds by fermentation. Biocatalysis may substantially reduce both production costs and environmental impact compared to other processes such as chemical synthesis. We partner with manufacturers of fine chemical compounds (flavors, fragrances, APIs, pigments, additives, intermediates, and more) in order to establish more sustainable manufacturing processes for a greener tomorrow. Biosyntia is located at the Novo Nordisk Foundation (NNF) Center for Biosustainability in Hørsholm, 25 kilometers north of Copenhagen.

Invetx

Series B in 2022
Invetx is a veterinary therapeutics company that develops protein-based therapeutics for animal health. Invetx's network includes animal and human health experts, veterinary scientists, and clinicians. The company's vision is of a global animal health industry that fully leverages biopharma technologies to deliver dramatically improved health outcomes for pets and farm animal populations.

Engimmune Therapeutics

Seed Round in 2022
Engimmune Therapeutics is a platform and product development company using cutting-edge technologies in the life sciences engineering highly potent and specific therapies based on T cell receptors (TCR) targeting solid tumors.

Qure AI

Series C in 2022
Qure AI is a healthtech startup that uses artificial intelligence assistance for medical imaging diagnostics. The company's mission is to make healthcare affordable and accessible using the power of artificial intelligence. They build deep learning solutions that aid physicians with routine diagnosis and treatment, allowing them to spend more time with patients. Qure AI was founded in 2016 and is based in Mumbai, Maharashtra.

Precirix

Series B in 2022
Camel-IDS develops radiopharmaceuticals for cancer patients. Its product, CAM-H2, treats HER2 positive cancers. It also engages in clinical development to treat breast cancer patients; and develops compounds for other cancer indications. The company was incorporated in 2014 and is based in Brussels, Belgium.

Rondo Therapeutics

Series A in 2022
Rondo Therapeutics is a therapeutic antibody discovery and development that creates novel bispecific antibodies that activate the immune system to fight cancer. The company was founded in 2021 and is headquartered in Hayward, California.

Biomason

Series C in 2022
Biomason is a developer of a building materials technology to produce biological cement-based building materials alternatives. Its bio cement production combines natural microorganisms and chemical processes to develop masonry materials at room temperature, which helps replace traditional clay and concrete, and the high energy consumption associated with standard manufacturing them, enabling builders to acquire alternative building materials that are produced carbon-free. Since 2012, the company has used microorganisms to grow sustainable, structural biocement® in ambient temperatures, harnessing the power of biotechnology to reinvent traditional cement and offer a planet-friendly alternative. Biocement will eliminate 25% of the concrete industry’s global carbon emissions by 2030. Biomason bio cement is in use in projects throughout the US and Europe, and bioLITH precast tile products are commercially available.

Centauri Therapeutics

Series A in 2022
Centauri Therapeutics is a UK-based biotechnology company dedicated to discovering and developing innovative molecules aimed at combating life-threatening diseases. The company utilizes its proprietary Alphamer technology, which involves chemically synthesized molecules that redirect naturally occurring antibodies to specific pathogens, enhancing the immune response against infections. Each Alphamer consists of two components: one binds to a cell-surface target on the pathogen, while the other presents specific epitopes that engage circulating antibodies. This approach has demonstrated the ability to trigger an immediate antibacterial immune response, effectively clearing infections. Centauri Therapeutics' flexible Chemistry Platform allows for the synthesis of these bifunctional molecules, which are applicable in treating various infectious diseases. Additionally, the company has formed a joint venture, Avvinity Therapeutics, with Horizon Discovery to advance immuno-oncology initiatives, combining Centauri's expertise in Alphamer technology with Horizon's capabilities in gene editing and oncology. Through collaborations in aptamer selection, drug discovery, chemistry, and immunology, Centauri Therapeutics aims to enhance its impact in the field of immunotherapy.

NMD Pharma

Venture Round in 2022
NMD Pharma is a clinical-stage biotech company that delivers life-transforming therapies for people living with neuromuscular diseases. They use ClC-1 Cl- ion channel inhibitors to treat neuromuscular diseases. Their translational muscle electrophysiology platform leverages in-depth knowledge of muscle physiology and muscular disorders to identify and develop first-class therapeutics for neuromuscular diseases that are unmet medically.

Metagenomi

Series B in 2022
Metagenomi uses metagenomics and machine learning to discover novel genome editing systems for therapeutics development. The company's metagenomics-powered discovery platform and analytical expertise reveal novel cellular machinery sourced from otherwise unknown organisms. Metagenomi forges these naturally evolved systems into powerful gene editing systems that are ultra-small, extremely efficient, highly specific, and have a decreased risk of the immune response. Metagenomi's goal is to revolutionize gene editing for the benefit of patients around the world. The company was founded in 2018 and is headquartered in Emeryville, California.

Verana Health

Series E in 2022
Verana Health is a digital health data company that delivers insights from unfiltered healthcare data with integrity to connect the dots between patient care and clinical research. Verana Health is exclusively entrusted by key specialty medical societies to manage data from real-world healthcare settings across more than 20,000 healthcare providers and 70 electronic health record systems. Its healthcare data ecosystem is powered by VeraQ™, a clinician-directed and AI-enhanced population health data engine that securely powers a data integrity feedback loop of nearly a half-billion raw, point-of-care health encounters. By applying advanced analytics to proprietary, curated datasets, Qdata™, Verana Health helps life sciences partners enhance evidence generation and speed clinical research that promote physicians’ quality of care and patients’ quality of life. For more information, visit www.veranahealth.com.

Zhenge Biotech

Series C in 2022
Zhenge Biotech is a macromolecular pharmaceutical contract development and manufacturing organisation.

21st.Bio

Venture Round in 2021
Developer of an innovative biological platform designed to focus on scaling up the manufacture of proteins and peptides. The company's platform develops the right large-scale production of molecules by testing them through various expressions such as fungi, yeast, or bacteria, enabling clients to get sustainable solutions for food, agriculture, and energy at attractive costs and quantities.

Asgard Therapeutics

Seed Round in 2021
Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies. Formed as a spin-off from Lund University, the Company is pioneering a gene therapy approach based on its proprietary TrojanDC technology, designed to set in motion immune responses based on the biological properties of professional antigen-presenting cells.

BIOMILQ

Series A in 2021
BIOMILQ is a women-owned and science-led start-up building a mammary biomanufacturing platform to produce bioauthentic human milk ingredients for better human health. By combining the unique capabilities of human mammary cells with a scalable biomanufacturing process, BIOMILQ aims to demonstrate the power of our platform through impact in early-life nutrition with ingredients that promote immune, gut, and neurological development.

Amolyt Pharma

Series B in 2021
Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders. Its programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism, and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism.

INBRACE

Series D in 2021
Swift Health Systems is a stealth stage medical device company developing INBRACE: a revolutionary, easy to use, wide indication, personalized orthodontic system hidden behind the teeth. Our patented self-guiding technology uses light and continuous forces to gently correct your smile with less pain and fewer doctor visits. INBRACE is FDA registered and a catalyst for disruption in orthodontics. INBRACE increases the number of people who will seek orthodontic treatment by addressing the top concerns for patients while driving practice growth for clinicians. Our platform leverages digital treatment planning, computer modeling, and direct digital manufacturing to create a scalable, patient customized solution that delivers the standard of care across the entire range of orthodontic cases.

Disc Medicine

Series B in 2021
Disc Medicine is a clinical-stage biopharmaceutical company focused on discovering, and developing innovative treatments for patients with severe hematologic disorders. The company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias and diamond-blackfan anemia.

Doctor Anywhere

Series C in 2021
Doctor Anywhere is a Singapore-based telehealth company that provides on demand healthcare solutions to help you lead happier, healthier lives. Their digital platform gives you quick access to health and wellness solutions, wherever you are. Their platform makes healthcare simple, seamless and convenient, and is optimised to help you manage your health in a way that best suits your lifestyle needs. With technology, better health outcomes are more achievable than ever before. They recognize modern-day struggles and are dedicated to improving healthcare services to suit our evolving lifestyle preferences.

Genomatica

Series C in 2021
Genomatica develops biobased process technologies that enable a better way to produce widely-used chemicals, from alternative feedstocks, with better economics, sustainability, and performance. Genomatica has earned widespread acclaim for its technology; has commercialized processes for the chemical butanediol (for biodegradable plastics and apparel) and for butylene glycol (cosmetics and personal care), and is working on bio-nylon. Awards include the Kirkpatrick Award, for “the most noteworthy chemical engineering technology commercialized in the world” and the ICIS Innovation Award for its Brontide(TM) butylene glycol.

Aristea Therapeutics

Series B in 2021
Aristea Therapeutics is a developer of novel therapies created for autoimmune diseases.The company's therapies include developing drugs, enabling inflammatory diseases patients to address their unmet medical needs.

Hemab

Series A in 2021
Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate, modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threatening complications. Hemab Therapeutics was established in 2017 in Copenhagen, Hovedstaden by Johan H. Faber and Mads Behrndt.

Muna Therapeutics

Series A in 2021
Muna Therapeutics is a private biopharmaceutical company that discovers and develops therapies that slow or stop devastating neurodegenerative diseases including Parkinson's, Alzheimer's, Frontotemporal Dementia, and Multiple Sclerosis.

Availity

Secondary Market in 2021
Availity, L.L.C. is a Jacksonville, Florida-based company that specializes in internet-based health information exchange services. Founded in 2001, Availity enhances the communication flow among healthcare providers, health plans, and other stakeholders. Its offerings include various solutions such as CareRead, which facilitates patient information entry via magnetic stripe-enabled member ID cards, and CareProfile, which provides access to electronic health records. The company also offers patient communication tools for online interactions and appointment requests, as well as CarePrescribe, an electronic prescribing system that ensures up-to-date medication information and drug interaction checks. Additionally, Availity’s CareCost Estimator determines patient financial responsibilities in real-time, while CareCollect streamlines the collection of patient payments through card swipes. Availity serves a diverse clientele, including physician offices, hospitals, integrated delivery networks, pharmacies, laboratories, and imaging centers.

Glycomine

Series B in 2021
Glycomine is early-stage biotech working on replacement therapies for rare diseases. There are approximately 7,000 rare disorders worldwide. Each day more are being discovered. 95% of rare diseases have not one single FDA-approved treatment. Glycomine develops therapeutics for diseases that have no treatment options.

Quanta

Series D in 2021
Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.

BBI Group

Acquisition in 2021
The BBI Group has been a trusted partner to some of the world’s leading diagnostic and healthcare organisations for over 25 years. Founded upon the success of the superior quality and performance of our gold reagents, our organisation has grown to incorporate 3 businesses delivering excellence in diagnostic assay development and manufacturing across a range of sectors, and the supply of consumer healthcare products.

Chromologics

Seed Round in 2021
Chromologics develops innovative natural food colorants. Chromologics is a Danish biotech spin-out from the Technical University of Denmark. We have developed a fungal biotech platform for the production of novel, natural colorants.

Noom

Series F in 2021
Noom is a psychology-based digital health platform powered by data, technology, and human coaches that helps millions of people meet their personal health and wellness goals from weight management to diabetes prevention to stress reduction. The company has been awarded multiple grants from the National Institutes of Health and was the first mobile application to be recognized by the Centers for Disease Control as a certified diabetes prevention program. Headquartered in New York City, Noom has been named one of Inc's Best Places to Work and Fortune’s Best Workplaces in Technology. To learn more about careers with Noom, visit https://www.noom.com/careers/jobs

Numab

Series C in 2021
Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases such as chronic inflammation and cancer. It features a plug-and-play platform that substantially reduces the random nature of the discovery process to predictably yield ready-to-develop multispecific biotherapeutics.

Hummingbird Bioscience

Series C in 2021
Hummingbird Bioscience uses systems biology to develop insights into disease biology and applies computationally guided platforms to discover and engineer breakthrough biotherapeutics. The company is pursuing a broad pipeline of first drug candidates across multiple challenging targets with strong biological validation and disease association, including lead assets: HMBD-001, an anti-HER3 antibody, and HMBD-002, an anti-VISTA antibody, for the treatment of cancer. Hummingbird has established strategic collaborations with Cancer Research UK and Amgen, and has been awarded a product development grant from the Cancer Prevention and Research Institute of Texas.

AMSilk

Series C in 2021
AMSilk produces and distributes high-quality silk biopolymers for use in textile products, medical devices, and cosmetics.

ADCendo

Series A in 2021
ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.

Halodoc

Series C in 2021
HaloDoc is a healthcare network platform. HaloDoc connects users to a network of 19,000 licensed doctors, 1,000 certified partner pharmacies through medical delivery service ApotikAntar, and licensed medical laboratory services. Users can communicate with these medical professionals via chat, video and voice call.

Exscientia

Series D in 2021
Exscientia combines human expertise with AI and machine learning to enhance drug discovery. The company focuses on precision engineering of medicine candidates, enabling faster and more efficient development of new treatments. By integrating innovative experimental techniques, Exscientia aims to improve patient outcomes and revolutionize the pharmaceutical industry.

Arcellx

Series C in 2021
Arcellx is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx’s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Arcellx’s lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory multiple myeloma (r/r MM) in an ongoing Phase 1 study. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the U.S. Food and Drug Administration. Arcellx is also advancing its dosable and controllable CAR-T therapy, ARC-SparX, into the clinic through two programs: ACLX-001 in r/r MM and ACLX-002 in relapsed or refractory acute myeloid leukemia.

Deep Branch Biotechnology

Series A in 2021
Deep Branch uses clean and renewable carbon and energy to create ingredients for a more sustainable food system. With a customer-focused research and development pipeline, it can quickly deliver high-quality, next-generation bio-based products to meet society’s demand for food and feed sustainably. By collaborating with local providers of strategic raw materials, Deep Branch can identify the best sites that offer sustainable input supply while helping develop the local economy. The company’s proprietary gas fermentation platform also uses sustainable and scalable feedstocks, strengthening its competitive edge in the global food and feed ingredients markets. Deep Branch has established strong partnerships across the value chain as it deploys its gas fermentation platform with a clear scale-up roadmap backed by world-leading investors and strategic partners. It also has a proven track record of integrating with carbon dioxide suppliers to deploy its technology efficiently and safely. Combining entrepreneurial drive with industrial experience, Deep Branch’s scientists and engineers produce ground-breaking innovations to meet market demand. Creating locally-produced ingredients with up to 60% smaller carbon footprints than traditional alternatives means Deep Branch’s products require no arable land and minimal water. With benefits such as these, the company is tackling the climate crisis and addressing biodiversity loss by helping secure the future of the global food system without consumers compromising on nutrition or quality.

StrideBio

Series B in 2021
StrideBio is a gene therapy company focused on developing genetic medicines with curative potential for patients with devastating conditions. It leverages its proprietary structure-inspired adeno-associated virus (AAV) vector engineering platform to create unique and differentiated vectors that improve upon naturally occurring AAV serotypes to overcome current limitations of first-generation gene therapies. The company was founded in 2015 and is headquartered in Durham, North Carolina.

BioPhero

Series A in 2021
BioPhero is a pioneer in providing low-cost bio-based pheromones for pest management.

Exscientia

Series C in 2021
Exscientia combines human expertise with AI and machine learning to enhance drug discovery. The company focuses on precision engineering of medicine candidates, enabling faster and more efficient development of new treatments. By integrating innovative experimental techniques, Exscientia aims to improve patient outcomes and revolutionize the pharmaceutical industry.

ZELP

Series A in 2021
ZELP aims to significantly reduce the environmental impact of the livestock industry.

Altasciences

Acquisition in 2021
Altasciences is a forward-thinking, mid-sized contract research organization offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.

Cyteir Therapeutics

Series C in 2021
Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir’s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug that was designed to inhibit RAD51-mediated homologous recombination and the repair of double-strand DNA breaks.

Vestaron

Series B in 2021
Vestaron is leading a peptide-based revolution in crop protection. The company is committed to providing growers with novel, effective, peptide-based biopesticides that address proven targets. Vestaron's peptides overcome existing resistance issues while offering a desired safety profile for workers, beneficial, and the environment. Vestaron has earned global recognition for its work, including the inaugural 2015 Bernard Blum Award for novel biocontrol solutions, the prestigious Green Chemistry Challenge Award from the U.S. Environmental Protection Agency and the American Chemical Society Green Chemistry Institute in 2020, and Best New Biologic Product in the 2021 Crop Science Awards.

IO Biotech

Series B in 2021
IO Biotech is a clinical stage biotech company developing disruptive immune therapies for the treatment of cancer. The pipeline of first-in-class immune modulating anti-cancer therapies is developed by a unique technology platform, T-win®, enabling the activation of T cells that are specific for immune-suppressive molecules. IO Biotech has a proven track record of progressing preclinical and clinical compounds. The two lead compounds targeting IDO and PD-L1 are in clinical development and several pipeline compounds are in pre-clinical phase.

Corwave

Series C in 2021
The CorWave LVAD utilizes an undulating disc wave pumping mechanism, replacing the high speed, high shear impeller of current continuous flow rotary pumps. The result is much less trauma to the blood, reducing clotting and bleeding complications. The high frequency actuation of the Corwave pump provides for pulsatile flow that mimics the action of the native heart. Current LVADs provide only continuous flow with no significant pulsation, due to the high inertia of their rotors. Its low power consumption and small size will facilitate totally implantablity with the incorporation of a wireless energy transfer system.

Hemab

Seed Round in 2020
Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate, modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threatening complications. Hemab Therapeutics was established in 2017 in Copenhagen, Hovedstaden by Johan H. Faber and Mads Behrndt.

Tempus

Series G in 2020
Tempus is a technology company improving precision medicine through the practical application of artificial intelligence in healthcare. Their platform is designed to analyze and interpret clinical and molecular data to help healthcare providers deliver more personalized and effective treatments.

Tempus

Debt Financing in 2020
Tempus is a technology company improving precision medicine through the practical application of artificial intelligence in healthcare. Their platform is designed to analyze and interpret clinical and molecular data to help healthcare providers deliver more personalized and effective treatments.

Reneo Pharmaceuticals

Series B in 2020
Reneo Pharmaceuticals is an operator of a pharmaceutical company used to develop therapies for patients with orphan metabolic diseases. It focuses on the development of treatments for genetic disorders associated with defects in energy metabolism resulting in myopathy that enable caregivers to improve the daily function and quality of life of patients suffering from these diseases by improving how their mitochondria work, preserving muscle function and preventing muscle injury, weakness, and wasting. The company was founded in 2014 and is headquartered in San Diego, California.

Edgewise Therapeutics

Series C in 2020
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Guided by its holistic drug discovery approach to targeting the muscle as an organ, Edgewise has combined its foundational expertise in muscle biology and small molecule engineering to build its proprietary, muscle focused drug discovery platform. Edgewise’s platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases.

MycoWorks

Series B in 2020
MycoWorks is a biotech company that provides non-plastic and non-animal materials to the market. Their mycelium products provide natural alternatives to plastic foams, textiles, and leather. Their products are made from bio-materials using fungal mycelium to create energy-efficient and biodegradable alternatives to plastic foams, synthetic textiles, engineered woods, and leather for use in aerospace, automobiles, apparel, and architectural interiors.

Stargazer Pharmaceuticals

Series A in 2020
Stargazer Pharmaceuticals is a pharmaceutical company that offers the therapy of standards disorder and manufacturer of pharmaceuticals products. It's also a Manufacturer of pharmaceuticals. The company is currently operating in Stealth mode.

The Protein Brewery

Series A in 2020
The Protein Brewery is a high-tech company that specializes in developing and making animal-free- based protein in a sustainable way. It's a spin-out from BioscienZ and is commercializing innovative protein production using fermentation. It was founded by Wim de Laat in 2019 and is based in Breda, Noord-Brabant, The Netherlands.

VectivBio

Venture Round in 2020
VectivBio is a clinical-stage biotechnology company bringing transformational medicines to patients with serious rare diseases. They are committed to pursuing rare diseases with well-defined biology that can be targeted with best-in-disease therapies that have the potential to meaningfully transform and improve the lives of patients and their families, not just provide an incremental improvement or benefit over the standard-of-care. It was founded as a spinout from Therachon, a biotechnology company acquired by Pfizer for its program in achondroplasia. VectivBio was incorporated in 2019 and is based in Basel, Switzerland.

Rappta Therapeutics

Series A in 2020
Rappta Therapeutics is a lead-optimization stage biopharmaceutical company. We are working on a first-in-class series of anti-cancer molecules that reactivate a key tumor suppressor, protein phosphatase 2A (PP2A).

Evotec

Post in 2020
Evotec is a drug discovery alliance and development partnership rapidly progressing innovative product approaches with pharmaceutical and biotechnology companies, academics, patient advocacy groups, and venture capitalists. Drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licencing of innovative drug candidates, and consulting arrangements.

Syndesi Therapeutics

Series A in 2020
Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Regulating synaptic transmission represents a promising approach to treating Alzheimer’s Disease and other disorders with cognitive impairment. Syndesi has an exclusive license to its platform technology from UCB, the leading company in SV2A research.

Galecto

Series D in 2020
Galecto develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, in which there is high unmet medical need. Galecto was founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.

Lava Therapeutics

Series C in 2020
Lava Therapeutics is a developer of a bispecific antibody platform used to engage gamma-delta T cells for the treatment of hematological and solid cancers. Its platform creates and develops next-generation γδ T cell engaging bispecific antibodies for the treatment of cancer as well as develop potent, safe, and cost-effective biopharmaceuticals that arm the immune system to recognize and destroy tumor cells that enable doctors to safely channel the immune system's response towards tumors.

ESCAPE Bio

Venture Round in 2020
Escape Bio is a clinical-stage biopharmaceutical company that develops small molecule drugs intended to treat neurodegenerative diseases. The company is developing therapeutics for the novel, precisely therapies for genetic neurodegenerative diseases. Escape Bio's pipeline includes candidates targeting known genetic drivers of multiple diseases, including ESB1609, a small molecule S1P5 receptor agonist for the treatment of CNS lysosomal storage disorders and ESB5070, a small molecule kinase inhibitor for Parkinson’s disease patients who have an LRRK2 G2019S variant and an Alzheimer's disease program targeting ApoE4. E-scape Bio was founded in 2015 and is headquartered in San Francisco, California, United States.

Chromologics

Seed Round in 2020
Chromologics develops innovative natural food colorants. Chromologics is a Danish biotech spin-out from the Technical University of Denmark. We have developed a fungal biotech platform for the production of novel, natural colorants.

ReViral

Series C in 2020
ReViral is a developer of antiviral drugs designed to help patients and enlarge the antiviral market by developing novel first-in-class compounds. The company's antiviral drugs is a fusion inhibitor of RSV which is a highly potent, novel small molecule and is being developed to treat RSV in patients with severe disease including neonates, enabling patients to be treated who are infected with respiratory syncytial virus (RSV) by developing novel compounds.

Mission Bio

Series C in 2020
Mission Bio delivers targeted solutions for high-impact applications with the Tapestri Platform. The Tapestri Platform is the industry’s first and only single-cell multi-omics platform, enabling genotype and phenotype from the same cell and precise detection of heterogeneity in disease progression and treatment response. Application areas include oncology blood cancers, solid tumors, and genome editing validation.

F2G

Venture Round in 2020
F2G is advancing its own patented compounds and technologies which will lead to the development of novel agents to treat serious fungal disease. The Company was founded on its proprietary genomics technology (MycoBank®) that identifies essential gene targets in fungi. Having received initial funding in 2002 the company then rapidly diversified into chemistry-driven discovery. They have also assembled an experienced development capacity.
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance. Praxis is applying insights from genetic epilepsies to broader neurological and psychiatric disorders, using our understanding of shared biological targets and circuits in the brain.

Verona Pharma

Post in 2020
Verona Pharma is a biotechnology company dedicated to discovering new drugs for the treatment of chronic respiratory diseases, such as asthma, allergic rhinitis (hay fever), chronic obstructive pulmonary disease (COPD) and cough. The company creates therapies to address unmet medical requirements in the treatment of respiratory disorders. Verona Pharma was established in 2005 by Clive Page in London, England.

Preventice Solutions

Series B in 2020
Preventice Solutions is a privately-held company that offers a portfolio of mobile cardiac health solutions and services. It is a developer of mobile health solutions and remote monitoring services, connecting patients, clinicians, and hospitals.

Reapplix

Series A in 2020
Reapplix ApS, a research and development company, identifies blood-derived proteins that improve wound healing, isolates them, and reapplies them to patients with chronic wounds. The company was founded in 2008 and is based in Birkerod, Denmark.

Bolt Biotherapeutics

Series C in 2020
Bolt Biotherapeutics is a biotechnology company that develops a platform for cancer immunotherapy. Its platform, Boltbody, is a cancer immunotherapy that consists of immune-stimulating antibody conjugates.

Freeline

Series C in 2020
Freeline is a clinical biotechnology company that develops transformative adeno-associated virus-vector-mediated systemic gene therapies. They use a designed AAV vector and capsid along with novel promoters and transgenes to deliver a functional copy of a therapeutic gene into human liver cells to express a functional level of the missing or dysfunctional protein into the patient’s bloodstream. Their development programs including clinical trials focus on developing products.

Checkmate Pharmaceuticals

Series C in 2020
Checkmate Pharma is a clinical-stage biopharmaceutical company developing a new approach for cancer immunotherapy. The clinical programs are focused on enabling more people with cancer to benefit from the promise of novel immunotherapies. They leveraging their expertise in the field of CpG oligonucleotides to discover and develop immunotherapies designed to increase the efficacy of existing immunotherapies and to provide new treatment options for patients and their healthcare providers. Checkmate Pharmaceutical was founded in 2015 and is headquartered in Cambridge, Massachusetts.

NodThera

Series B in 2020
NodThera is a Cambridge (UK) headquartered biotech engaged in innate immune/ inflammasome research. Their leading project is focused on developing inhibitors of the NLRP3 inflammasome for the treatment of inflammatory and neuroinflammatory diseases.

Antag Therapeutics

Venture Round in 2020
Antag Therapeutics is a biotechnology company developing metabolic and anti-obesity therapeutic drugs. It offers the development of peptide-based GIP receptor antagonists in order to monitor dietary-related metabolic diseases through the infusion to decrease blood flow and lipid uptake in adipose tissue.

Exscientia

Series C in 2020
Exscientia combines human expertise with AI and machine learning to enhance drug discovery. The company focuses on precision engineering of medicine candidates, enabling faster and more efficient development of new treatments. By integrating innovative experimental techniques, Exscientia aims to improve patient outcomes and revolutionize the pharmaceutical industry.

IO Biotech

Debt Financing in 2020
IO Biotech is a clinical stage biotech company developing disruptive immune therapies for the treatment of cancer. The pipeline of first-in-class immune modulating anti-cancer therapies is developed by a unique technology platform, T-win®, enabling the activation of T cells that are specific for immune-suppressive molecules. IO Biotech has a proven track record of progressing preclinical and clinical compounds. The two lead compounds targeting IDO and PD-L1 are in clinical development and several pipeline compounds are in pre-clinical phase.

Avalyn Pharma

Series B in 2020
Avalyn Pharma is a biopharma company that advances therapies for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other severe respiratory diseases. Its therapies rapidly advance AP01 for the treatment of IPF, provides additional pipeline candidates for IPF, improve the care and outcomes of severe respiratory diseases, and develop novel inhaled therapeutics. Avalyn Pharma was established in 2011 and is headquartered in Seattle, Washington.

Kebotix

Series A in 2020
Kebotix is a high-tech materials discovery and production company. It is to reinvent the materials industry and enable a new age of discovery of new materials using AI, machine learning, and robotics. It was founded in 2017 and is headquartered in Cambridge, Massachusetts.

Tempus

Series G in 2020
Tempus is a technology company improving precision medicine through the practical application of artificial intelligence in healthcare. Their platform is designed to analyze and interpret clinical and molecular data to help healthcare providers deliver more personalized and effective treatments.

MycoWorks

Series A in 2020
MycoWorks is a biotech company that provides non-plastic and non-animal materials to the market. Their mycelium products provide natural alternatives to plastic foams, textiles, and leather. Their products are made from bio-materials using fungal mycelium to create energy-efficient and biodegradable alternatives to plastic foams, synthetic textiles, engineered woods, and leather for use in aerospace, automobiles, apparel, and architectural interiors.

Spruce Biosciences

Series B in 2020
Spruce Biosciences is a biopharmaceutical company developing therapies for rare diseases that target the endocrine system. The company is driven by a mission to develop meaningful therapies for patients with rare diseases affecting the hypothalamic-pituitary-adrenal. They are committed to transforming the quality of life for patients who have been underserved by scientific innovation.

Inventiva Pharma

Post in 2020
Inventiva Pharma is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology. They have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging these assets and expertise, they are advancing two clinical candidates in three indications, as well as a deep pipeline of earlier stage programs.

HepaRegeniX

Series B in 2020
HepaRegeniX is developing drugs for treating acute and chronic liver diseases that effectively restore the regenerative capacity of hepatocytes. The therapeutic concept is founded on research by Professor Lars Zender’s group at the University Hospital Tübingen, which identified mitogen-activated protein (MAP) kinase kinase 4 (MKK4) as a key regulator of liver regeneration. Work by Professor Zender’s team showed that using small RNA molecules to suppress MKK4 gene expression restored the regenerative capacity of hepatocytes, even in severely diseased livers. Founded in 2015, HepaRegeniX is developing small-molecule MKK4 inhibitors to treat liver disorders, potentially including nonalcoholic steatohepatitis.

Aligos Therapeutics

Series B in 2020
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.

VectivBio

Series A in 2020
VectivBio is a clinical-stage biotechnology company bringing transformational medicines to patients with serious rare diseases. They are committed to pursuing rare diseases with well-defined biology that can be targeted with best-in-disease therapies that have the potential to meaningfully transform and improve the lives of patients and their families, not just provide an incremental improvement or benefit over the standard-of-care. It was founded as a spinout from Therachon, a biotechnology company acquired by Pfizer for its program in achondroplasia. VectivBio was incorporated in 2019 and is based in Basel, Switzerland.

NorthSea Therapeutics

Series B in 2020
NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics. The team leverages Structurally Engineered Fatty Acid (SEFA) technology to develop novel and unique therapeutic approaches targeting metabolic, inflammatory and fibrotic diseases. The SEFA technology has generated pipeline candidates with a broad array of inter- and independent biological effects, improving dyslipidemia, insulin resistance, hepatic inflammation and fibrosis in diverse models.

WCG

Private Equity Round in 2019
WCG offers solutions for clinical and technology. They serve science, medicine, and organizations that develop products and therapies to improve human health. Their services include study planning, site optimization, patient engagement, scientific, and market insight services.

Draupnir Bio

Seed Round in 2019
Draupnir Bio intends to develop a new type of cholesterol-lowering medicine that prevents blood clots in the heart more effectively than the current medicine. The company is developing a platform for exploring the glycome to develop novel therapeutics, based on array technology, protein chemistry, and advanced carbohydrate chemistry. The company is able to synthesize, screen, and select highly potent and specific heparan sulfate glycomimetic drug candidates in cardiovascular, inflammatory, and infectious diseases.

Disc Medicine

Series A in 2019
Disc Medicine is a clinical-stage biopharmaceutical company focused on discovering, and developing innovative treatments for patients with severe hematologic disorders. The company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias and diamond-blackfan anemia.

Allievex

Series A in 2019
Allievex is a clinical-stage biotechnology company

Cyteir Therapeutics

Series B in 2019
Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir’s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug that was designed to inhibit RAD51-mediated homologous recombination and the repair of double-strand DNA breaks.

Reapplix

Venture Round in 2019
Reapplix ApS, a research and development company, identifies blood-derived proteins that improve wound healing, isolates them, and reapplies them to patients with chronic wounds. The company was founded in 2008 and is based in Birkerod, Denmark.

INBRACE

Series C in 2019
Swift Health Systems is a stealth stage medical device company developing INBRACE: a revolutionary, easy to use, wide indication, personalized orthodontic system hidden behind the teeth. Our patented self-guiding technology uses light and continuous forces to gently correct your smile with less pain and fewer doctor visits. INBRACE is FDA registered and a catalyst for disruption in orthodontics. INBRACE increases the number of people who will seek orthodontic treatment by addressing the top concerns for patients while driving practice growth for clinicians. Our platform leverages digital treatment planning, computer modeling, and direct digital manufacturing to create a scalable, patient customized solution that delivers the standard of care across the entire range of orthodontic cases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.